<\/p>\n
Valent<\/strong> is a 80 \/ 160 mg valsartan tablet<\/strong> from a WHO-GMP certified manufacturer — an angiotensin II receptor blocker (ARB)<\/strong>. ARBs are first-line antihypertensive therapy<\/strong> alongside ACE inhibitors, CCBs, and thiazides per NICE, AHA\/ACC, and ESC\/ESH guidelines — and are the preferred alternative when an ACE inhibitor is not tolerated<\/strong> (usually because of the dry cough, which affects up to 20% of ACE-inhibitor users). Introduced 1996 (Novartis as Diovan<\/strong>). The ARB with the most heart-failure evidence after losartan; component of the sacubitril\/valsartan combination (Entresto) that replaced ACE inhibitors as first-line HF-REF therapy in the 2021 ESC guidelines. Active drug (not a prodrug); no metabolic activation. Half-life 6 hours but effect lasts 24 hours via tight AT1 receptor binding. Typical hypertension dose: start 80 mg once daily (40 mg in elderly, volume-depleted, or hepatic impairment), target 160 mg once daily<\/strong>. Component of sacubitril\/valsartan (Entresto)<\/strong> — the angiotensin receptor-neprilysin inhibitor (ARNI) class. PARADIGM-HF trial (2014) showed sacubitril\/valsartan reduced cardiovascular mortality by 20% vs enalapril in HF-REF, changing first-line HF-REF therapy. Standard valsartan monotherapy remains an option in patients unable to afford or tolerate sacubitril\/valsartan. Absolutely contraindicated in pregnancy<\/strong> (all trimesters — same teratogenic profile as ACE inhibitors: fetal renal agenesis, oligohydramnios, pulmonary hypoplasia), bilateral renal artery stenosis<\/strong>, and concurrent sacubitril\/valsartan or aliskiren<\/strong>. Monitor potassium and creatinine.<\/p>\n<\/div>\n \ud83d\udce6 Every order is covered by our Reshipment Assurance Policy<\/strong><\/a> \u2014 if your parcel does not arrive within 20 business days, we reship it.<\/p>\n Our generic medications are sourced from WHO-GMP certified manufacturers and shipped worldwide in discreet, plain packaging \u2014 no medication name on the parcel exterior. Card payments are routed through a regulated processor (statement descriptors include a regulated card-payment processor \u2014 never “MedsBase” or any medication name). Crypto and SEPA bank transfer are also accepted. Every order is backed by our Reshipment Assurance Policy.<\/p>\n Valent is an oral 80 \/ 160 mg valsartan tablet from a WHO-GMP certified manufacturer, supplied in 30-180 tablets. Introduced 1996 (Novartis as Diovan<\/strong>). The ARB with the most heart-failure evidence after losartan; component of the sacubitril\/valsartan combination (Entresto) that replaced ACE inhibitors as first-line HF-REF therapy in the 2021 ESC guidelines. Active drug (not a prodrug); no metabolic activation. Half-life 6 hours but effect lasts 24 hours via tight AT1 receptor binding.<\/p>\n ARBs block the angiotensin II type 1 (AT1<\/sub>) receptor<\/strong> directly, preventing angiotensin II from binding and exerting its vasoconstrictor and aldosterone-releasing effects. This is one receptor downstream of where ACE inhibitors act (which block angiotensin II formation) and produces equivalent clinical effects:<\/p>\n Clinical consequence of this mechanism: ARBs achieve equivalent BP control to ACE inhibitors with lower rates of cough (0-3% vs 20% for ACEi) and angioedema (roughly 30-50% lower than ACEi, though not zero).<\/p>\n Pivotal trial evidence:<\/strong> Val-HeFT (2001)<\/strong> — valsartan in HF-REF reduced hospitalisation. VALIANT (2003)<\/strong> — valsartan non-inferior to captopril in post-MI left-ventricular dysfunction. VALUE (2004)<\/strong> — valsartan vs amlodipine in high-risk hypertension; slight advantage to amlodipine on stroke + MI endpoints, driven largely by more rapid BP control with amlodipine.<\/p>\n Hypertension:<\/strong><\/p>\n Heart failure:<\/strong> 40 mg twice daily, titrate to 160 mg twice daily (Val-HeFT target)<\/p>\n Administration:<\/strong> once daily, with or without food. Take at the same time each day for stable BP control.<\/p>\n Monitoring:<\/strong><\/p>\n Discontinuation:<\/strong> no withdrawal syndrome; however, abrupt stop causes BP rebound over days. Taper over 1-2 weeks when stopping.<\/p>\n Common (>1%, usually mild):<\/strong><\/p>\n Uncommon but important:<\/strong><\/p>\n Breastfeeding:<\/strong> avoid in the first weeks after delivery of a premature infant. Long-term use in established breastfeeding is generally considered acceptable given low milk transfer, but alternative antihypertensives (propranolol, nifedipine) are preferred when possible.<\/p>\nWhy order from MedsBase<\/h3>\n
What Is Valent?<\/h2>\n
How Valsartan Lowers Blood Pressure<\/h2>\n
\n
Approved and Evidence-Based Uses<\/h2>\n
\n
Valent Dosage<\/h2>\n
\n
\n
Side Effects<\/h2>\n
\n
\n
Contraindications<\/h2>\n
\n
Drug Interactions<\/h2>\n
\n
ARB Class at a Glance<\/h2>\n